Epstein-Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantation.
There is a growing interest in the evaluation of non-myeloablative conditioning therapy for allogeneic stem cell transplantation. Such regimens are expected to produce less toxicity while allowing both engraftment and a graft-versus-disease effect from the large number of donor-derived immunocompetent T lymphocytes given with the stem cells. Heavy immunosuppression used in recipients may have unexpected consequences. We describe the occurrence of a fatal Epstein-Barr virus-associated B cell lymphoproliferative disease (BLPD) early after such a non-myeloablated allogeneic peripheral blood stem cell transplant in a heavily pretreated patient.
Milpied
N
N
Department of Hematology, Centre Hospitalier Universitaire, Nantes, France.
Coste-Burel
M
M
Accard
F
F
Moreau
A
A
Moreau
P
P
Garand
R
R
Harousseau
J L
JL
D000328:Adult; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000209:etiology* / Q000821:virology; D019653:Myeloablative Agonists / Q000627:therapeutic use; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous
D019653:Myeloablative Agonists